DRI Healthcare Trust (DHT-U) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DRI Healthcare Trust (DHT-U) has a cash flow conversion efficiency ratio of 0.053x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($26.92 Million) by net assets ($503.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of DRI Healthcare Trust to measure how much of total assets are equity-financed.
DRI Healthcare Trust - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how DRI Healthcare Trust's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DRI Healthcare Trust cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
DRI Healthcare Trust Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DRI Healthcare Trust ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Yankon Group Co Ltd
SHG:600261
|
0.022x |
|
RaySearch Laboratories AB (publ)
ST:RAY-B
|
0.112x |
|
Changshu Automotive Trim Co
SHG:603035
|
-0.004x |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
-0.033x |
|
Wuxi Xinhongtai ElecTech
SHG:603016
|
0.034x |
|
Sichuan Xichang Electric Power Co Ltd
SHG:600505
|
0.101x |
|
Santacruz Silver Mining Ltd. Common Shares
NASDAQ:SCZM
|
0.042x |
|
Guangdong Chant Group Inc
SHE:002616
|
0.235x |
Annual Cash Flow Conversion Efficiency for DRI Healthcare Trust (2020–2024)
The table below shows the annual cash flow conversion efficiency of DRI Healthcare Trust from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see DHT-U market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $527.53 Million | $155.41 Million | 0.295x | +114.05% |
| 2023-12-31 | $561.50 Million | $77.28 Million | 0.138x | -33.85% |
| 2022-12-31 | $372.34 Million | $77.47 Million | 0.208x | -14.17% |
| 2021-12-31 | $378.99 Million | $91.86 Million | 0.242x | +100.00% |
| 2020-12-31 | $-352.00 | $91.86 Million | -260977.273x | -- |
About DRI Healthcare Trust
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.